BioWorld

Sep. 29, 2004

View Archived Issues

AtheroGenics Soars 64 Percent On AGI-1067 Phase IIb Results

AtheroGenics Inc. saw its share value skyrocket on positive clinical trial results that revealed its lead drug candidate cut plaque buildup in heart disease patients. (BioWorld Today) Read More

Nabi's Phase II Demonstrates NicVAX Helps Smokers Quit

Read More

Exelixis Buying X-Ceptor Therapeutics For $22.3M

Read More

Seattle Genetics In ADC Deal With Bayer Pharmaceuticals

Read More

Correction

Read More

OXIS Gives HaptoGuard Rights To Lead Product For Up To $21M

Read More

Other News To Note

Read More